Excitotoxicity Markers and the Clinical-radiological Progression After a Demyelinating Event: a Prospective Pilot Study

Multiple Sclerosis Clinical Trial

— EXCEED  

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02523703
• Other study ID #: 06-063
• Status: Completed
• Phase: N/A
• Start date: September 10, 2007
• Est. completion date: February 23, 2015

Study information

• Verified date: August 2020
• Source: University Hospital, Caen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Multiple sclerosis (MS) is an inflammatory disease of the central nervous system, beginning most often in subjects aged 20-40 years. In France, thanks to recent studies reported during general states of MS in 2006, the prevalence is estimated at 65.5 / 100,000 population (96.3 / 100,000 women and 41.9 / 100,000 men) and incidence at 7.91 per 100,000. In Lower Normandy, the incidence of MS is estimated to 4.45 / 100,000 inhabitants or 60 new cases per year.

The primary objective of this pilot study is to assess the levels of glutamate and aspartate (excitotoxicity markers) and their repercussions on the clinical and radiological outcome in 40 patients experiencing an event demyelinating central nervous system.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: February 23, 2015
• Est. primary completion date: February 15, 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Man or woman between 18 and 60 years old.

• Patient with one or more type of inflammatory events of Central system suggestive of demyelinating disease (multiple sclerosis, neuromyelitis optical Devic extensive myelitis)

• No treatment with corticosteroids for less than 1 month

• Need for a lumbar puncture performed in the etiologic

• Need a brain MRI performed within the etiologic

• Patient who signed informed consent

Exclusion Criteria:

• Secondary progressive MS

• Any cons-indication for lumbar puncture

• Any contra-indication to MRI

• Minor patient or patient major under guardianship

Related Conditions & MeSH terms

• Multiple Sclerosis

Intervention

Biological:
• glutamate and aspartate

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Caen

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	glutamate concentration (in nM)	comparison between MS patients and controls	baseline